Annual report pursuant to Section 13 and 15(d)

Asset Acquisition And License Agreements (Details)

v3.3.1.900
Asset Acquisition And License Agreements (Details) - USD ($)
1 Months Ended 12 Months Ended
Feb. 28, 2015
Mar. 31, 2013
Dec. 31, 2015
Dec. 31, 2013
Merck | CERC-301        
Asset Acquisition And License Agreement [Line Items]        
Total Cost of License Agreement   $ 1,500,000    
Other Commitment     $ 750,000  
Merck | CERC-301 | Research and development expense        
Asset Acquisition And License Agreement [Line Items]        
Asset acquisition payments       $ 750,000
Merck | COMT Inhibitor        
Asset Acquisition And License Agreement [Line Items]        
Asset acquisition payments       $ 200,000
Merck | COMT Inhibitor | Royalty Commitment        
Asset Acquisition And License Agreement [Line Items]        
Term of royalty obligation     10 years  
Merck | COMT Inhibitor | Maximum | Development Milestone Commitment        
Asset Acquisition And License Agreement [Line Items]        
Potential Additional Milestone Commitment     $ 6,200,000  
Lilly | CERC-501        
Asset Acquisition And License Agreement [Line Items]        
Other Commitment     $ 250,000  
Term of the study     9 months  
Lilly | CERC-501 | Development Milestone Commitment        
Asset Acquisition And License Agreement [Line Items]        
Potential Additional Milestone Commitment     $ 19,000,000  
Lilly | CERC-501 | Sales Milestone Commitment        
Asset Acquisition And License Agreement [Line Items]        
Potential Additional Milestone Commitment     $ 30,000,000  
Lilly | CERC-501 | Royalty Commitment        
Asset Acquisition And License Agreement [Line Items]        
Term of royalty obligation     11 years  
Lilly | CERC-501 | Research and development expense        
Asset Acquisition And License Agreement [Line Items]        
Asset acquisition payments $ 750,000